Using Anti-TNF Therapy After 24 Weeks of Pregnancy Appears Safe, Effective: Study
Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood of relapse of inflammatory bowel disease (IBD) in pregnant women and fewer premature deliveries, according to a new report. In addition, the numbers of Cesarean sections, stillbirths, serious infections, and small or large weight for gestational size were similar in patients who continued or discontinued anti-TNF treatment after 24 weeks.
@raheman Discontinuation of anti-TNF treatment was associated with increased IBD activity and consequently with an increased rate of preterm birth. These results provide strong evidence supporting the recommendation of maintaining anti-TNF throughout pregnancy in women with IBD